Follow us on Twitter
twitter icon@FreshPatents


Monoclonal Antibody patents

      

This page is updated frequently with new Monoclonal Antibody-related patent applications.




 High-throughput single cell sorting using microbubble well arrays patent thumbnailHigh-throughput single cell sorting using microbubble well arrays
The present invention provides a microfabricated device and methods for high throughput single cell screening of a heterogeneous population. The present invention is partly based upon but not limited to sorting by monitoring cell secreted factors that accumulate in time (hours, days, weeks) as cells are cultured in the microbubble well niche the architecture of which facilitate the accumulation.
Nidus Biosciences, Llc


 Humanized monoclonal antibodies and methodsof use patent thumbnailHumanized monoclonal antibodies and methodsof use
The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene vh1-69. This antibody is derived from mab g6 and recognizes the same epitope.
Dana-farber Cancer Institute, Inc.


 Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis patent thumbnailPharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular


 Monoclonal antibody against human prpc and use thereof patent thumbnailMonoclonal antibody against human prpc and use thereof
A monoclonal antibody against human prpc protein capable of reducing the expression level of transcription factor twist1 in a targeting mode and inducing macrophage and nk cells to target to rectal cancer tumor cells. The combined drug therapy with the antibody and cetuximab also exhibits inhibitory effect on tumor better than administration of the antibody or cetuximab alone..
Institute Of Zoology, Chinese Academy Of Sciences


 Erbb2 signaling and nerve regeneration patent thumbnailErbb2 signaling and nerve regeneration
Use of an inhibitor of the erbb2 receptor for treatment or repair of nerves and/or nerve tissues is provided. The inhibitor includes an antibody, in particular, a monoclonal antibody, for example, herceptin.
The Hospital For Sick Children


 Anti-despr monoclonal antibody targeted therapy and imaging for cancer and stroke patent thumbnailAnti-despr monoclonal antibody targeted therapy and imaging for cancer and stroke
Provided herein are novel compositions comprising anti-despr antibodies and fragments thereof derived from 6g8g7 and 7c5b2 anti-despr variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-despr antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-despr antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as despr-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments..
Trustees Of Boston University


 Detection methods employing hcv core lipid and dna binding domain monoclonal antibodies patent thumbnailDetection methods employing hcv core lipid and dna binding domain monoclonal antibodies
The present disclosure provides detection methods employing hcv core lipid binding domain and dna binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of hcv core protein and the dna binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of hcv core protein..
Icahn School Of Medicine At Mount Sinai


 Detection methods employing hcv core lipid and dna binding domain monoclonal antibodies patent thumbnailDetection methods employing hcv core lipid and dna binding domain monoclonal antibodies
The present disclosure provides detection methods employing hcv core lipid binding domain and dna binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of hcv core protein..
Abbott Laboratories


 Method of providing monoclonal auto-antibodies with desired specificity patent thumbnailMethod of providing monoclonal auto-antibodies with desired specificity
Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human auto-immunosome and corresponding monoclonal antibody reservoir are provided.
Immunoqure Ag


 Use of anti-ccr5 antibodies in graft versus host disease patent thumbnailUse of anti-ccr5 antibodies in graft versus host disease
This composition and method provides for a method for reducing gvhd in a human subject which comprises administering to the subject at a predefined interval effective gvhd-reducing doses of (a) a humanized antibody designated pro 140, or of (b) an anti-ccr5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of gvhd.
Cytodyn Inc.


Hybridoma cell lines (my-c-cc0c2-259-1 a4) and use thereof for producing a monoclonal antibody against human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)

Monoclonal antibodies, which can be produced in vitro, against cardiac epitopes of the human my-c are produced by generating myeloma cell clones that produce such specific antibodies having epitope specificity. These monoclonal antibodies allow, among other things, the creation of an enzyme-linked immunosorbent assay (elisa) for the specific, cross-reactivity-free quantitative determination of my-c in serum, plasma, whole blood or other body fluid.
Martin- Luther-universitaet Halle-wittenberg

Humanized monoclonal antibodies and methods of use

The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope.
The Brigham And Women's Hospital

Compositions and methods for treating fatty tissue buildup

The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
The Metrohealth System

Enrichment and characterization of human corneal endothelial cells (hcenc) with novel monoclonal antibody

This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hcencs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed peroxiredoxin-6 (prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal en dothelial cells from a mixture of cell.. .
Singapore Health Services Pte Ltd

Antibodies for the prevention or the treatment of bleeding episodes

The invention relates to an isolated monoclonal antibody that specifically binds to the d4 domain of vwf, competes for binding to vwf d4 domain with adamts13 and partially inhibits adamts 13 -mediated degradation of vwf. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one cdr having a sequence selected from the group consisting of seq id no: 3 for h-cdr1, seq id no: 4 for h-cdr2 and seq id no: 5 for h-cdr3 and a light chain wherein the variable domain comprises at least one cdr having a sequence selected from the group consisting of seq id no: 7 for l-cdr1, seq id no: 8 for l-cdr2 and seq id no: 9 for l-cdr3.
UniversitÉ De Droit Et De La SantÉ De Lille 2

Use of annexin a3 as a diagnostic and prognostic biomarker and therapeutic target for treating hepatocellular carcinoma

Annexin a3 (anax3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (hcc) and the utilization of a monoclonal antibody against anxa3 or antisense polynucleotide against anxa3 mrna for the suppression or treatment of hcc, alone or in combination with other hcc treatment. Monoclonal antibody against anxa3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance..
The University Of Hong Kong

Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof

Compositions and methods for the treatment or prevention of dengue virus infection in a vertebrate subject are provided. In particular, human neutralizing monoclonal antibodies to dengue virus isolated from ebv immortalized b cells derived from patients who have recovered from dengue infection are disclosed.
Dso National Laboratories

Methods of enhancing antibody-dependent cellular cytotoxicity

The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an adcc enhancer molecule..
Ventirx Pharmaceuticals, Inc.

Monoclonal antibody and vaccine targeting filamentous bacteriophage

Described here is a method for reducing or preventing pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds pf-family bacteriophage, or (b) a vaccine against pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a coab protein of pf-family bacteriophage or fragment thereof..
University Of Washington

Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

Eculizumab, a humanized monoclonal antibody against c5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (pnh). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global phase iii trial.
Alexion Pharmaceuticals, Inc.

Antibodies specific for hyperphosphorylated tau and methods of use thereof

The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (phf) tau (ps396), as well as to methods of using these molecules and their tau binding fragments in the treatment of alzheimer's disease and tauopathies.. .
H. Lundbeck A/s

Anti-glucosaminidase passive immunization for staphylococcus aureus infections

The present invention is directed to a monoclonal antibody that binds specifically to a staphylococcus aureus glucosaminidase and inhibits in vivo growth of s. Aureus.
University Of Rochester

Anti-metalloprotease antibody for diagnosis and treatment of cancers

Expression of proteolytically active, high molecular weight adam protease is relatively increased in tumour cells that also express the putative tumour stem cell marker cd133. An antibody or antibody fragment such as 8c7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight adam10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma..
Ludwig Institute For Cancer Research Ltd

Screening assays and methods

Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other.
President And Fellows Of Harvard College

Anti-krs monoclonal antibody and use thereof

The present invention relates to an anti-lysyl-trna synthetase (krs) antibody selectively binding to krs, and a use thereof and, more specifically, to an antibody binding to human krs or a fragment thereof, a method for producing the same, and a composition containing the same for diagnosing cancer, autoimmune diseases or inflammatory diseases. The antibody or fragment thereof of the present invention specifically binds to human krs, and enables krs detection and inhibition due to the absence of cross-linkage reactivity with the other proteins including the same ars family, and thus the antibody or fragment thereof can be used to detect krs and diagnose krs-related diseases, i.e., cancer, autoimmune diseases or inflammatory diseases..
Medicinal Bioconvergence Research Center

Novel targeting glycoproteins to treat cancer

The present disclosure relates to a method of inhibiting tumor growth. More specifically, the present disclosure relates to the use of monoclonal antibodies for targeting truncated o-glycans on glycoproteins to inhibit activation of pro-survival ceil signaling pathways, to inhibit tumor growth.
Board Of Regents Of The University Of Nebraska

Anti-human probdnf monoclonal antibody, and uses thereof in pains

The present invention provides an anti-human probdnf monoclonal antibody, and uses thereof in pains. Specifically, the present invention provides uses of antibody polypeptide of tenth to 128th amino acid in a specific recognition pro-bdnf precursor protein structural domain, a nucleic acid sequence for coding the antibody polypeptide, a carrier comprising the nucleic acid sequence, a host comprising the carrier, a pharmaceutical composition comprising the antibody, and the antibody in the preparation of drugs used for alleviating and/or suppressing chronic pains..
Shanghai Yile Biotechnology Limited

Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

Eculizumab, a humanized monoclonal antibody against c5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (pnh). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global phase iii trial.
Alexion Pharmaceuticals, Inc.

Soluble mic neutralizing monoclonal antibody for treating cancer

Disclosed are compositions and methods relating to antibodies that bind soluble major histocompatibility complex class i chain-related (smic). Specifically, disclosed are antibodies designed or selected to inhibit smic (e.g.
University Of Washington Through Its Center For Commercialization

Monoclonal antibodies to fibroblast growth factor receptor 2

The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.. .
Galaxy Biotech, Llc

Ca6 antigen-specific cytotoxic conjugate and methods of using the same

Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the ca6 glycotope.
Immunogen, Inc.

Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies

The present invention concerns compositions and methods of use of anti-hla-dr antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease.
Immunomedics, Inc.

Anti-human igm monoclonal antibody and immunoassay using the same

By selecting a monoclonal antibody that reacts with human igm on the basis of evaluation of reactivity with human igm in solution, a novel monoclonal antibody capable of agglutinating human igm by itself and performing a practical immunoagglutination assay has been obtained, and the objectives above have been thus achieved.. .

Anti-tissue factor monoclonal antibody

Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed..
Nanocarrier Co., Ltd.

Use of antagonists of the interaction between hiv gp120 and a4b7 integrin

Methods are provided for the treatment of a hiv infection. The methods can include administering to a subject with an hiv infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the hiv infection.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Therapeutic pharmaceutical composition employing anti-slc6a6 antibody

The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to slc6a6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native slc6a6 or a native polypeptide of an extracellular region of slc6a6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases..
Order-made Medical Research Inc.

Biological products

There is disclosed antibody molecules containing at least one cdr derived from a mouse monoclonal antibody having specificity for human cd22. There is also disclosed a cdr grafted antibody wherein at least one of the cdrs is a modified cdr.
Ucb Biopharma Sprl

Monoclonal antibody cocktails for treatment of ebola infections

Antibody variants originating from the monoclonal antibody 13c6, and wherein the n-glycosylation site within the constant region of the heavy chain contains a glycan that is either wild-type or largely devoid of fucose residues, will bind ebola virus glycoprotein and provide surprising efficacy in treating animals or humans infected with ebola virus when used in combination with one or more additional anti-ebola mabs. Such antibody cocktails are vastly superior to other known monoclonal antibodies or monoclonal antibody combinations in treating animals and humans infected with the ebola virus..

Reticulocyte growth factor and preparing method and application thereof

A reticulocyte growth factor (rgf) and a preparing method and application thereof is provided. The factor is separated and purified from impurities of α1-antitrypsin (from human plasma), and the fragment of a precursor of the antitrypsin is determined, and has very high function of promoting the generation of the reticulocyte of mice.
Nanjing Biyoukang Biotechnology Co., Ltd.

Monoclonal antibody cocktails for treatment of ebola infections

Antibody variants originating from the monoclonal antibody 13c6, and wherein the n-glycosylation site within the constant region of the heavy chain contains a glycan that is either wild-type or largely devoid of fucose residues, will bind ebola virus glycoprotein and provide surprising efficacy in treating animals or humans infected with ebola virus when used in combination with one or more additional anti-ebola mabs. Such antibody cocktails are vastly superior to other known monoclonal antibodies or monoclonal antibody combinations in treating animals and humans infected with the ebola virus..

Augmentation of oncology immunotherapies by pterostilbene containing compositions

Compositions and methods useful to enhancing, improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses.
Therapeutic Solutions International, Inc.

Monoclonal antibody capable of binding integrin alpha 10 beta 1

The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular i-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the deutsche sammlung von microorganismen und zellkulturen gmbh under the accession number dsm acc2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular i-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited.
Xintela Ab

Diagnosis and treatment of cancer using anti-itm2a antibody

Disclosed is a monoclonal antibody binding to an itm2a protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as ewing's sarcoma, t cell leukemia, t cell lymphoma, acute myeloid leukemia, b cell tumor, and multiple myeloma.
Chugai Seiyaku Kabushiki Kaisha

Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies

Provided herein are methods of treating an epidermal growth factor receptor (egfr) extracellular domain (ecd) mutant cancer in a human patient by administering to the patient an oligoclonal anti-epidermal growth factor receptor (anti-egfr) antibody combination (e.g., mm-151, comprising a first monoclonal antibody (p1x), a second monoclonal antibody (p2x), and a third monoclonal antibody (p3x), wherein p1x, p2x and p3x are in a 2:2:1 molar ratio). In one embodiment, the cancer comprises at least one mutation in the extracellular domain of egfr selected from the group consisting of egfr r451c, s464l, k467t, g465r, g465e, i491m, and s492r..
Merrimack Pharmaceuticals, Inc.

Il-31 monoclonal antibody formulations

The invention provides humanized mouse anti-human il-31 antibodies and antibody fragments that are capable of binding il-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of il-31.. .
Merck Serono S/a

High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides

The invention relates to an oligonucleotide including one or more modified nucleoside bases having the structure -b-l-a wherein for each of the modified nucleosides a is independently a monosaccharide or oligosaccharide, l is a linker molecule, and b is independently a pyrimidine or pyridine base linked to the sugar-phosphate backbone of the oligonucleotide; and wherein the oligonucleotide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nm. Immunogenic conjugates that include the oligonucleotide, and pharmaceutical compositions that include the oligonucleotide or the immunogenic conjugate are also disclosed.
Brandeis University

Multivalent glycopeptides that tightly bind to target proteins

The invention relates to a glycopolypeptide that includes one or more modified amino acid residues having a sidechain comprising a monosaccharide or an oligosaccharide, wherein the glycopolypeptide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nm. Immunogenic conjugates that include the glycopolypeptide, and pharmaceutical compositions that include the glycopolypeptide or the immunogenic conjugate are also disclosed.
Brandeis University

Cancer treatment using viruses and camptothecins

Mammalian subjects having a neoplasm are treated with a virus and a camptothecin compound, for example irinotecan or topotecan. The virus is selected from the group consisting of a newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a sindbis virus, a picornavirus, and a myxoma virus.
Wellstat Biologics Corporation

Human anti-il-33 neutralizing monoclonal antibody

An object of the present invention is to provide an antibody having antagonistic effect against il-33, in particular an isolated human anti-il-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-il-33 monoclonal antibodies were identified, human anti-il-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to il-33 was specified by introducing mutations in the complementarity-determining regions.
Mitsubishi Tanabe Pharma Corporation

Anti-dog ige monoclonal antibody, and light-chain variable region and heavy-chain variable region of anti-dog ige monoclonal antibody

Solution: the present invention is dna encoding a heavy-chain variable region consisting of the amino acid sequence represented by seq id no: 2 or 6 and dna encoding a light-chain variable region consisting of the amino acid sequence represented by seq id no: 4 or 8, and an anti-dog ige monoclonal antibody which binds to dog ige, containing these variable regions or a functional fragment thereof which binds to dog ige.. .

Inhibitors of complement activation

The invention relates to factor d inhibitors, which bind to factor d and block the functional activity of factor d in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like fab, f(ab′)2 and fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds.
Genentech, Inc.

Broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibody

The invention provides a method for obtaining a broadly neutralizing antibody (bnab), including screening memory b cell cultures from a donor pbmc sample for neutralization activity against a plurality of hiv-1 species, cloning a memory b cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory b cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the env proteins in native or monomeric form, as well as to inhibit infection of hiv-1 species from a plurality of clades.
International Aids Vaccine Initiative



Monoclonal Antibody topics:
  • Monoclonal Antibody
  • Monoclonal
  • Antibodies
  • Recombinant
  • Immune Response
  • Polypeptide
  • Amino Acid
  • Amino Acid Sequence
  • Therapeutics
  • Specificity
  • Major Histocompatibility Complex
  • Compatibility
  • Immunotherapy
  • Stimulator
  • Immunostimulator


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Monoclonal Antibody for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Monoclonal Antibody with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.1507

    file did exist - 2857

    1 - 1 - 52